TIGER is an EU funded Horizon 2020 project developing a highly innovative therapeutic mRNA-based cancer vaccine to target hard to treat cancers.

TIGER builds on the current revolution in mRNA-based technologies that offer unparalleled opportunities for developing new therapeutics targeting cancers with high unmet clinical needs

The TIGER project

TIGER will advance the development of an intravenous (IV) platform technology that uses proprietary lipid nanoparticles (LNP) for a new class of mRNA-therapeutics with the potential to revolutionise care for patients with hard-to-treat cancers.

Successful clinical development should deliver an innovative affordable new therapy that yields a significant improvement on the current therapeutic approach and standard of care for all patients suffering from HPV16-related cancers. A phase 1/2a clinical study will deliver the clinical evidence to define the most appropriate strategy to advance into pivotal phase 2b/3 studies bring the therapy closer to market.

The project also advances exciting and innovative biomedical diagnostics to provide new tools to support later stage clinical studies, future oncology therapy development and patient stratification. Since our IV mRNA cancer vaccine platform can use virtually any antigen, any type of cancer could be targeted with the right antigens. This project will enable further application of the technology in a wide range of cancers using other tumour antigens.

Our objectives


To conduct an early stage clinical study to investigate the novel drug EI-201 for safety, tolerability, and clinical efficacy in patients with HPV16+ cancers.


Identify novel imaging biomarkers using radiomics to evaluate early tumour response and investigate tumour responses to EI-201 treatment.


Develop and validate a novel assay to measure circulating tumour DNA (ctDNA) derived from HPV16+ tumours which could be applied as a biomarker for measuring the effect of cancer therapies on HPV+ tumour burden.

Clinical programme

Our clinical programme advances the candidate products through critical early safety and efficacy studies to prepare for late stage studies. If successful we expect first regulatory approval for first or second line metastatic cancer patients. This should move cancer vaccines quickly to standard-of-care status once the benefit: risk profile is proven in the target metastatic population.

Stay tuned for more information about the TIGER project